AAL

Analysts: Buy This Biotech Stock Now

Raymond James thinks ZYME stock could double

Aug 2, 2018 at 1:41 PM
facebook X logo linkedin


The shares of biotech Zymeworks Inc (NYSE:ZYME) are higher today, thanks to some positive analyst attention. Last night -- and despite the stock's relatively blase reaction to earnings yesterday -- Raymond James reiterated its "outperform" rating and "high degree of conviction on the stock," saying it "strongly encourage[s] investors to take advantage of current valuation" ahead of upcoming clinical updates, including Zymeworks' R&D day in October. In addition, the analyst reiterated a $27 price target on ZYME -- in uncharted territory, and more than double the equity's current perch. Likewise, Citigroup this morning upgraded ZYME stock to "buy" from "neutral," and lifted its price target to $20. 

Zymeworks shares are now on pace to end atop their 10-day moving average, which has been guiding the equity lower since its June 1 all-time high of $26, touched after the company reported well-received data on ZW25 at the American Society of Clinical Oncology conference. What's more, $26 represents double ZYME's initial public offering (IPO) price of $13. At last check, ZYME was up 7.1% to trade at $13.29, set to snap a seven-day run south of its IPO price.

ZYME stock chart august 2

While the stock has surrendered nearly half its value since the June 1 peak, it's no stranger to upbeat analyst attention. Five of the seven analysts following ZYME already deem it worthy of a "buy" or better rating, and the consensus 12-month price target is a lofty $24.29 -- an 83% premium to current levels.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.